氨基末端脑钠肽前体与急性心肌梗死的研究进展
- 格式:pdf
- 大小:1.14 MB
- 文档页数:4
脑钠肽在心力衰竭中的研究进展申岩;高瑞敏;康玲玲;徐建峰;岳华;张守军【摘要】Brain natriuretic peptide (BNP) is a peptide hormone that is synthesized mainly in heart.When the heart wall pressure increases,the secretion of BNP gets increasing,thus the levels of BNP and severity of heart failure are closely related.Recently,as an important biomarker of heart failure,BNP shows amount of applications in thediagnosis,treatment,disease evaluation,treatment,prognosis and drug evaluation of heart failure.This paper summarizes the progress of BNP in the research of heart failure,and discusses the clinical significance of BNP in order to improve the insight of BNP in the treatment of heart failure.%脑钠肽是主要在心脏部位合成的一种肽类激素.当心室壁压力增高时,其分泌量随之增加,心衰严重程度与其血浆含量水平密切相关.脑钠肽作为心脏衰竭的一个重要生物标志物,近年来其在心衰的诊断、治疗、病情评估、治疗、预后以及药物评价方面均具有诸多应用.本文通过总结脑钠肽在心衰疾病研究中的国内外进展,论述脑钠肽在上述过程中的临床意义,为提高脑钠肽在心衰治疗方面的认识提供借鉴.【期刊名称】《中国医药导报》【年(卷),期】2017(014)032【总页数】4页(P35-38)【关键词】脑钠肽;心力衰竭;研究进展【作者】申岩;高瑞敏;康玲玲;徐建峰;岳华;张守军【作者单位】河北省唐山市工人医院分院心内科,河北唐山063000;河北省唐山市工人医院分院心内科,河北唐山063000;河北省唐山市工人医院分院心内科,河北唐山063000;河北省迁安燕山医院心内科,河北迁安063000;河北省迁安燕山医院心内科,河北迁安063000;河北省唐山市第三医院呼吸科,河北唐山063000【正文语种】中文【中图分类】R541.61心力衰竭是指各种原因引起的心脏结构或功能异常所导致的心室充盈或心脏射血能力受损综合征[1]。
1816 世界睡眠医学杂志WorldJournalofSleepMedicine2020年10月第7卷第10期October.2020,Vol.7,No.10重组人脑利钠肽在急性心肌梗死后心力衰竭治疗中的应用价值张晓康 沈磊(中国科学技术大学附属第一医院/安徽省立医院,合肥,230001)摘要 目的:探究重组人脑利钠肽在急性心肌梗死(AMI)后心力衰竭(HF)治疗中的应用价值。
方法:选取2019年4月至2020年4月中国科学技术大学附属第一医院收治的AMI后HF患者78例作为研究对象,随机分为对照组和观察组,每组39例。
对照组患者采用硝酸甘油治疗,再此基础上,观察组患者采用rhBNP治疗。
比较2组患者的心率、中心静脉压以及氨基末端B型利钠肽前体(NT ProBNP)情况。
结果:观察组患者的心率、中心静脉压以及NT ProBNP水平均显著降低,差异有统计学意义(P<0 05);2组患者治疗前PSQI评分差异均无统计学意义(P>0 05),治疗后PSQI评分均显著下降(P<0 05),治疗后观察组PSQI各项评分及PSQI总分均低于对照组(P<0 05)。
结论:rhBNP对AMI后HF患者的治疗具有显著的效果,值得推广使用。
关键词 重组人脑利钠肽;急性心肌梗死;心力衰竭ApplicationValueofRecombinantHumanBrainNatriureticPeptideintheTreatmentofHeartFailureafterAcuteMyocardialInfarctionZHANGXiaokang,SHENLei(TheFirstAffiliatedHospitalofUniversityofScienceandTechnologyofChina/AnhuiProvincialHospital,Hefei230001,China)Abstract Objective:Toexploretheapplicationvalueofrecombinanthumanbrainnatriureticpeptideinthetreatmentofheartfailureafteracutemyocardialinfarction Methods:Select78casesofpostAMIHFpatientsadmittedtothefirstaffiliatedHospitaloftheUniversityofScienceandTechnologyofChinafromApril2019toApril2020,Randomlydividedintocontrolandobservationgroups,39casesineachgroup Thecontrolgroupwastreatedwithnitroglycerin,Onthisbasis,rhBNPtreatmentwasusedintheob servationgroup theheartrate,centralvenouspressure,andaminoterminalBnatriureticpeptideprecursors(NT ProBNP)werecom paredinthe2groups Results:Theheartrate,centralvenouspressureandNT ProBNPlevelsofobservationgroupweresignificantlyreduced,thedifferencewassignificant(P<0 05);therewasnodifferenceinPSQIscoresbeforetreatmentbetweenthetwogroups(P>0 05),PSQIscoreaftertreatmentAllofthemdecreasedsignificantly(P<0 05) ThePSQIscoresandtotalPSQIscoresofrhBNPtreatmentgroupwerelowerthanthoseofcontrolgroupaftertreatment(P<0 05) Conclusion:rhBNPhasasignificanteffectonthetreatmentofHFpatientsafterAMI,anditisworthpopularizing.Keywords Recombinanthumanbrainnatriureticpeptide;Acutemyocardialinfarction;Heartfailure中图分类号:R543 3;R338 63文献标识码:Adoi:10.3969/j.issn.2095-7130.2020.10.063 急性心肌梗死(AcuteMyocardialInfarction,AMI)是由急性和持续性缺血以及冠状动脉缺氧引起的一种心肌坏死。
血浆氨基末端脑钠肽前体与急性心肌梗死相关性临床研究贾明理;李昌;夏豪;曾彬【摘要】目的探讨氨基末端脑钠肽前体(NT-proBNP)对急性心肌梗死(AMI)诊断的临床意义.方法选取2012年5月至2014年10月在我院心内科住院诊断为急性心肌梗死患者188例(AMI组)及诊断为非急性心肌梗死患者114例(对照组),统计患者基本临床资料及入院24h内实验室检查结果,分析NT-proBNP与AMI的相关性.结果 AMI组与对照组相比,在年龄、性别、高血压史、吸烟史、饮酒史、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)上未见统计学差异,糖尿病史、NT-proBNP、肌酸激酶同工酶(CK-MB)、肌红蛋白(MYO)、超敏肌钙蛋白Ⅰ(ultra-TnⅠ)、丙氨酸氨基转氨酶(ALT)、天门冬氨酸氨基转移酶(AST)、血糖(Glu)比较,差异有统计学意义.NT-proBNP与ultra-TnⅠ之间存在良好的相关关系(r2=0.746,r=0.864,P<0.01).ROC曲线显示,AUCM-proBNP=0.952,Cut-offNT-proBNP=246.82 pg/ml,诊断急性冠脉综合征灵敏度为87.9%,特异度为81.3%.结论氨基末端脑钠肽前体对急性心肌梗死的早期诊断具有较好的诊断价值.【期刊名称】《中国心血管病研究》【年(卷),期】2015(013)001【总页数】4页(P20-23)【关键词】氨基末端脑钠肽前体;急性心肌梗死;相关性【作者】贾明理;李昌;夏豪;曾彬【作者单位】435200湖北省黄石市,阳新县人民医院心血管内科;湖北省中山医院心血管内科;武汉大学人民医院心血管内科;武汉大学人民医院心血管内科【正文语种】中文【中图分类】R542.2+2急性心肌梗死(AMI)是指急性心肌缺血性坏死,是心血管病患者死亡的首要原因[1]。
氨基末端脑钠肽前体(NT-proBNP)在诊断心力衰竭及评价心力衰竭患者预后价值的重要性已得到证实[2]。
重组人脑利钠肽治疗老年急性心肌梗死致心力衰竭临床效果和安全性研究童随阳;夏豪;王欣;李磊【期刊名称】《临床误诊误治》【年(卷),期】2015(000)008【摘要】Objective To evaluate the clinical efficacy and safety of recombinant human brain natriuretic peptide ( rhBNP) in elderly patients with acute heart failure caused by acute myocardial infarction. Methods 120 cases of acute heart failure caused by acute myocardial infarction during June 2012 and September 2014 in our hospital were randomly divid-ed into two groups;experimental group (60 cases) and control group (60 cases). Experimental group was given rhBNP treat-ment, and control group was given Nitroglycerin treatment. The basic clinical data and laboratory results were collected. The clinical curative effect, all the parameters and hypotension during hospitalization of two groups were observed and compared. The incidence of major adverse cardiovascular events including malignant arrhythmia, cardiogenic shock and sudden cardiac death during hospitalization were also observed and analyzed. Results There was no significant difference in the general clin-ical data and blood biochemical indicators between the two groups (P>0. 05). The total effective rate was 86. 67% in treat-ment group, and 66. 67% in control group, the difference was statistically significant between the two groups(P<0. 05). Both groups had a greater reduction of heart rate ( HR) , blood NT-proBNP level, and a greater improvement of urine volume, systemic blood pressure( SBP) , diastolic blood pressure ( DBP) and left ventricle ejection fraction ( LVEF) after therapy com-pared with that before therapy, and the difference was statistically significant between the two groups (P<0. 05). The experi-mental group had a greater reduction of serum creatinine ( Cr) level after therapy, and the difference was statistically signifi-cant for the two groups (P<0. 05). The experimental group had a greater improvement of HR, urine volume, blood NT-proB-NP level, Cr, LVEF compared with control group after therapy, and the difference was statistically significant for the two groups (P<0. 05). During hospitalization, the incidence rate of hypotension and malignant arrhythmia was lower in experi-mental group than that of control group, and the difference was statistically significant between the two groups ( P<0. 05 ) . Conclusion rh-BNP in elderly patients with acute heart failure caused by myocardial infarction can improve clinical symp-toms and hemodynamics. Recombinant human brain natriuretic peptide is an effective, reliable and safe medication in the treatment of acute heart failure caused by acute myocardial infarction.%目的:探讨重组人脑利钠肽( rhBNP)治疗老年急性心肌梗死致心力衰竭的临床效果及安全性。
N-端脑利钠肽前体(NT-proBNP)在急性冠状动脉综合征的研究进展摘要:脑钠肽是具有多种生物学活性的多肽,N-端脑利钠肽前体(NT-proBNP)在心力衰竭的鉴别诊断、疾病预后、心功能分级等方面得到广泛应用,同时N-端脑利钠肽前体(NT-proBNP)指标在缺血性心脏病中也逐渐应用,但是仅仅依靠N-端脑利钠肽前体指标诊断,无法对患者病情进行准确诊断,因此,本次研究对N-端脑利钠肽前体(NT-proBNP)在急性冠状动脉综合征的研究进行相关综述。
关键词:N-端脑利钠肽前体;急性冠状动脉综合征;研究急性冠状动脉综合征是冠心病急性发作形式,为冠心病严重类型,急性冠状动脉综合征病理特征是指冠脉动脉内不稳定粥样斑块破裂基础上、血小板激活、血管栓塞、冠状动脉痉挛收缩引起的急性心肌缺血,而N-端脑利钠肽前体(NT-proBNP)为目前心血管疾病常见的诊断性标志物,主要集中于心血管疾病鉴别诊断、预后评估等方面[1]。
近年来,N-端脑利钠肽前体(NT-proBNP)研究也逐渐延伸直至心血管疾病以外的领域,例如肾功能不全、神经系统疾病等,但是由于非心血管系统疾病中研究较少,日后还需要进一步进行研究,目前,N-端脑利钠肽前体(NT-proBNP)和心肌缺血性疾病关系的研究内容较少[2],因此,本次研究对N-端脑利钠肽前体(NT-proBNP)在急性冠状动脉综合征的研究进行分析,见下文。
1 N-端脑利钠肽前体(NT-proBNP)的来源N-端脑利钠肽前体(NT-proBNP)作为利钠肽类的一种多胎激素,在1988年被提出,主要是从猪脑中所分离的[3]。
人类的N-端脑利钠肽前体(NT-proBNP)主要来源于人体心脏、脊髓、大脑等组织中,与N-端脑利钠肽前体(NT-proBNP)一样,人体外周血中N-端脑利钠肽前体(NT-proBNP)主要由机体心室肌细胞所分泌,故此人体血浆内N-端脑利钠肽前体(NT-proBNP)水平能够将心室的功能状态进行充分反映。